التفاصيل البيبلوغرافية
| العنوان: |
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014). |
| المؤلفون: |
Passalacqua, Rodolfo, Lazzarelli, Silvia, Donini, Maddalena, Montironi, Rodolfo, Tambaro, Rosa, De Giorgi, Ugo, Pignata, Sandro, Palumbo, Raffaella, Ceresoli, Giovanni Luca, Conte, Gianluca Del, Tonini, Giuseppe, Morelli, Franco, Nolè, Franco, Panni, Stefano, Rondini, Ermanno, Guida, Annalisa, Zucali, Paolo Andrea, Doni, Laura, Iezzi, Elisa, Caminiti, Caterina |
| المصدر: |
BMC Cancer; 7/19/2017, Vol. 17, p1-10, 10p, 5 Charts, 2 Graphs |
| مصطلحات موضوعية: |
CANCER chemotherapy, UROTHELIUM, CANCER treatment, DRUG efficacy, CLINICAL trials, PLATINUM, ANTINEOPLASTIC agents, COMPARATIVE studies, EPITHELIUM, RESEARCH methodology, MEDICAL cooperation, PROGNOSIS, RESEARCH, URINARY organs, VINBLASTINE, EVALUATION research, TREATMENT effectiveness, RETROSPECTIVE studies, TRANSITIONAL cell carcinoma, TUMORS, THERAPEUTICS |
| مصطلحات جغرافية: |
ITALY |
| مستخلص: |
Background: Vinflunine is the only chemotherapeutic agent shown to improve survival in platinum-refractory patients with metastatic transitional cell carcinoma of the urothelium (TCCU) in a phase III clinical trial, which led to product registration for this indication in Europe. The aim of this study was to assess the efficacy of vinflunine and to evaluate the prognostic significance of risk factors in a large, unselected cohort of patients with metastatic TCCU treated according to routine clinical practice.Methods: This was a retrospective multicenter study. Italian cancer centers were selected if, according to the Registry of the Italian Medicines Agency (AIFA), at least four patients had been treated with vinflunine between February 2011 and June 2014, after first- or second-line platinum-based chemotherapy. The primary objective was to test whether the efficacy measured by overall survival (OS) in the registration study could be confirmed in routine clinical practice. Multivariate analysis was carried out using Cox proportional hazard model.Results: A total of 217 patients were treated in 28 Italian centers. Median age was 69 years (IQR 62-76) and 84% were male; Eastern Cooperative Oncology Group performance status (ECOG PS) was ≥ 1 in 53% of patients. The median number of cycles was 4 (IQR 2-6); 29%, 35%, and 36% received an initial dose of 320 mg/m2, 280 mg/m2 or a lower dose, respectively. Median progression-free survival (PFS) and OS for the entire population was 3.2 months (2.6-3.7) and 8.1 months (6.3-8.9). A complete response was observed in six patients, partial response in 21, stable disease in 60, progressive disease in 108, with a disease control rate of 40%. Multivariate analysis showed that ECOG PS, number of metastatic sites and liver involvement were unfavorable prognostic factors for OS. Toxicity was mild, and grade 3-4 adverse effects were mainly: neutropenia (9%), anemia (6%), asthenia/fatigue (7%) and constipation (5%).Conclusions: In routine clinical practice the results obtained with VFL seem to be better than the results of the registration trial and reinforce evidence supporting its use after failure of a platinum-based chemotherapy. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Cancer is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder